0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Carcinogenicity of Lipid-Lowering Drugs

Marco Pahor, MD
JAMA. 1996;275(19):1480. doi:10.1001/jama.1996.03530430023028.
Text Size: A A A
Published online

To the Editor.  —In their article, Drs Newman and Hulley1 reviewed available data about potential carcinogenicity of lipid-lowering drugs and concluded that "most cholesterol-lowering drugs cause or promote cancer in rodents" and "[u]se of cholesterol-lowering drugs should be restricted to those at high risk of short-term CHD death." The authors addressed the issue only partially and failed to report the alternative view that statins may instead protect against cancer. There is emerging evidence that the HMG-CoA reductase inhibitor lovastatin can induce apoptosis in vitro in various cell lines, including tumor cells.2,3 Such an effect was dose dependent and was observed at low doses (100 nmol/L). The suspected carcinogenic effects are likely to occur at much higher concentrations. Apoptosis or genetically programmed cell death is an efficient mechanism for eliminating cancer cells and, therefore, for aborting cancer growth.4 Anticancer drugs act mainly by inducing apoptosis, and HMG-CoA reductase

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();